Allovir Inc expected to post a loss of 16 cents a share - Earnings Preview

Kalaris Therapeutics

30/04/2024 17:26

* Allovir Inc  ALVR.OQ   ALVR.O  is expected to show no
change in
quarterly revenue when it reports  results on May 2 (estimated)
for the period ending January 1 0001
    * 
    * ​LSEG's mean analyst estimate for Allovir Inc is for a
loss
of 16 cents per share. 
    * The current average analyst rating on the shares is "sell"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and 3 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Allovir Inc
is
$1.00​, above​ its last closing price of $0.81. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.46       -0.43      -0.36     Beat    15.9
 Sep. 30 2023  -0.41       -0.42      -0.39     Beat    6.3
 Jan. 1 0001   -0.43       -0.45      -0.48     Missed  -6.7​
 Mar. 31 2023  -0.46       -0.46      -0.44     Beat    5.4
 ​​Dec.        -0.56       -0.54      -0.37     Beat    31.9
 31 2022                                                
 Sep. 30 2022  -0.52       -0.53      -0.50     Beat    5.1​
 Jun. 30 2022  -0.73       -0.73      -0.69     Beat    5.5
 Mar. 31 2022  -0.80       -0.80      -0.69     Beat    13.4
 This summary was machine generated April 30 at 16:26 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)